TRPC6 and autism spectrum disorder: Collectively, these findings nominate BT11 for experimental validation (e.g., Trp680/Lys676 mutagenesis and electrophysiology), guide the synthesis of next-generation analog series, and suggest that BT11 (and related analogs) could serve as potential therapeutic leads for autism spectrum disorder via TRPC6 activation.